426 related articles for article (PubMed ID: 11170388)
1. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
[TBL] [Abstract][Full Text] [Related]
6. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
7. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA.
Leroy D; Kajava AV; Frei C; Gasser SM
Biochemistry; 2001 Feb; 40(6):1624-34. PubMed ID: 11327821
[TBL] [Abstract][Full Text] [Related]
8. Bioflavonoids as poisons of human topoisomerase II alpha and II beta.
Bandele OJ; Osheroff N
Biochemistry; 2007 May; 46(20):6097-108. PubMed ID: 17458941
[TBL] [Abstract][Full Text] [Related]
9. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
10. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
11. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
12. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Pitts SL; Jablonksy MJ; Duca M; Dauzonne D; Monneret C; Arimondo PB; Anklin C; Graves DE; Osheroff N
Biochemistry; 2011 Jun; 50(22):5058-66. PubMed ID: 21548574
[TBL] [Abstract][Full Text] [Related]
13. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison.
Bender RP; Lindsey RH; Burden DA; Osheroff N
Biochemistry; 2004 Mar; 43(12):3731-9. PubMed ID: 15035644
[TBL] [Abstract][Full Text] [Related]
16. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity.
Bender RP; Jablonksy MJ; Shadid M; Romaine I; Dunlap N; Anklin C; Graves DE; Osheroff N
Biochemistry; 2008 Apr; 47(15):4501-9. PubMed ID: 18355043
[TBL] [Abstract][Full Text] [Related]
17. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
[TBL] [Abstract][Full Text] [Related]
18. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
19. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
20. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
